PURA CBD Pet Products Acquisition Could Close Next Week Opening $1 Billion Market
February 20 2020 - 8:32AM
InvestorsHub NewsWire
PURA CBD Pet Products Acquisition
Could Close Next Week Opening $1 Billion Market
Dallas, TX -- February 20, 2020 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced plans to close the acquisition of a CBD
Infused Pet Products operation next week. PURA made an offer
to acquire the CBD Infused Pet Products operation just last week
and the seller has accepted the offer which entails a royalty
payment in exchange for PURA funding the CBD Infused Pet Products
marketing launch. The CBD pet products market is anticipated
to reach $1.16
billion in the U.S. alone by 2022. The seller currently provides concierge pet
services through a mobile app portal and already has a thriving
client base anticipated to help accelerate the sales growth of the
CBD Infused Pet Products under the PURA umbrella. The
acquisition is currently scheduled to close next week on Thursday,
February 27th, 2020 subject to the drafting, review and
approval of documents.
PURA recently launched a campaign to
acquire CBD infused beverage, edible and topical operations and
also announced closing on a $5 million investment to fund the
acquisition campaign. The $5 million investment is structured as a
debt facility whereby funds can be drawn as needed to fund
acquisitions. The drawn funds would be secured by the
acquired asset and the debt can be repaid in stock at $0.10 per
share.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024